The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2016
Filed:
May. 04, 2010
Suzanne L. Topalian, Brookeville, MD (US);
Florence a Depontieu, Lyons, FR;
Donald F. Hunt, Charlottesville, VA (US);
Jeffrey Shabanowitz, Charlottesville, VA (US);
Jie Qian, Somerset, NJ (US);
Victor H. Engelhard, Crozet, VA (US);
Angela Lee Zarling, Charlottesville, VA (US);
Suzanne L. Topalian, Brookeville, MD (US);
Florence A Depontieu, Lyons, FR;
Donald F. Hunt, Charlottesville, VA (US);
Jeffrey Shabanowitz, Charlottesville, VA (US);
Jie Qian, Somerset, NJ (US);
Victor H. Engelhard, Crozet, VA (US);
Angela Lee Zarling, Charlottesville, VA (US);
The Johns Hopkins University, Baltimore, MD (US);
University of Virginia Patent Foundation, Charlottesville, VA (US);
Abstract
We characterized a total of 175 HLA-DR-associated phosphopeptides using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing and comparative analysis. Many were derived from source proteins which may have roles in cancer development, growth and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome 'fingerprints'. We generated HLA-DRβ1*0101-restricted CD4T cells specific for a phospho-MART-1 peptide identified in two melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen presenting cells as well as for intact melanoma cells. MHC II-restricted phosphopeptides recognizable by human CD4T cells are potential targets for cancer immunotherapy.